ALK and neuroblastoma: Lorlatinib (PF‐06463922), a third‐generation ROS1 and ALK inhibitor, has been found to be effective against NB cells and against ALK‐mutated xenograft mouse models (both F1174L and F124C), as well as crizotinib‐resistant xenografts.225